Is Supernus Pharmaceuticals (SUPN) Still Worth A Look After Its Valuation Reset?

Why Supernus Pharmaceuticals Is Back On Investors’ Radar

A fresh report flagging Supernus Pharmaceuticals (SUPN) for unexciting sales trends, tighter free cash flow and a forward P/S of 2.7x has pushed the stock back into focus for valuation minded investors.

Recent trading tells a mixed story. The 1 day share price return declined 4.36% and the 90 day share price return is down 16.66% at a last close of US$40.18. However, total shareholder return over three and five years remains positive, suggesting longer term holders in Supernus Pharmaceuticals have still seen gains despite the recent loss of momentum.

Balance the recent pressure on Supernus Pharmaceuticals by comparing it with a hand picked 32 high quality undervalued stocks that has stronger cash generation and cleaner entry valuations.

The share price reset and mixed track record for Supernus Pharmaceuticals put the spotlight on one issue: Does the current P/S of 2.7x still give buyers a reasonable trade off between risk and potential upside?

Most Popular Narrative: 35% Undervalued

The most followed narrative on Supernus Pharmaceuticals puts fair value at $61.75 a share compared with the last close at $40.18. This frames the current discussion around whether the CNS platform potential is fully reflected in the price.

The current valuation implies the share price does not fully reflect a CNS portfolio generating about $2.2 billion of pro forma revenue and $888 million of adjusted EBITDA, with anticipated cost synergies and a balance sheet near 1x net leverage.

See why 8 investors see Supernus Pharmaceuticals as 35% undervalued.

Result: Fair Value of $61.75 (UNDERVALUED)

Still, the thesis around Supernus Pharmaceuticals depends on merger synergies being realized effectively and on product momentum translating into revenue growth that exceeds its past five-year average.

Find out about the key risks to this Supernus Pharmaceuticals narrative.

Another View On Supernus Pharmaceuticals’ Valuation

The market is pricing Supernus Pharmaceuticals at a P/S of 2.8x. Peers on average are closer to 1.6x, while the fair ratio points to 6.2x. That gap signals both premium risk against peers and potential upside if sentiment ever moves toward the fair ratio. Which side of that trade-off appears more reasonable to you?

See what the numbers say about this price, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

On balance, the Supernus Pharmaceuticals story so far leans optimistic, especially around upside claims, yet the valuation gap still divides opinion among investors. If you want to move beyond headlines and see exactly what others view as the bright spots, start with the 3 key rewards

Looking For More Ideas Beyond Supernus Pharmaceuticals?

If Supernus Pharmaceuticals has you rethinking your next move, now is the moment to scan wider and line up a few fresh candidates on your watchlist.

• Target higher quality potential by reviewing a curated mix of companies trading on attractive terms through the 32 high quality undervalued stocks.
• Strengthen your downside protection by focusing on businesses with sturdy finances using the list of solid balance sheet and fundamentals (25 results).
• Get ahead of the crowd by spotting lesser known opportunities screened for fundamentals through the 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com